Key takeaways:
- Topline results are expected for sura-vec, ixo-vec and 4D-150.
- Therapies are under investigation to help patients maintain vision long term.
WAIKOLOA, Hawaii — The recent progress and future development of gene therapy could help patients with wet age-related macular degeneration maintain vision, according to a speaker at Retina 2026.
Allen C. Ho, MD, of Wills Eye Hospital, said gene therapy started in the subretinal space with gene replacement therapy for Leber congenital amaurosis, and since that first FDA approval in 2017, there have been 30 gene therapies approved across all of medicine.
“We’re bringing it back to the retina,” he said
n 2025, the FDA approved Encelto (revakinagene taroretcel-lwey, Neurotech Pharmaceuticals) for the treatment of macular telangiectasia type 2. Ho said this approval will be followed by topline results for other therapies, including subretinal sura-vec (surabgene lomparvovec, AbbVie, Regenxbio), intravitreal ixo-vec (ixoberogene soroparvovec, Adverum Biotechnologies, Lilly) and intravitreal 4D-150 (4DMT).
Read more: Gene therapies may help patients maintain vision in AMD long term
Source: Healio